Evogene Ltd. — Form SCHEDULE 13D/A
Filed August 7, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
L.I.A. Pure Capital Ltd. purchased 216,300 American Depositary Shares of Evogene Ltd. across six transactions between August 3–6, 2026, at prices ranging from $0.51 to $0.68 per share, for a total aggregate value of approximately $133,000. Each ADS represents one ordinary share (par value NIS 0.20). This represents a Schedule 13D/A amendment filing disclosing the accumulation activity.
Why this rating
Routine insider/related-party share accumulation over ~4 days; modest dollar amount (~$133k) and share count suggest sub-material stake-building; no control shift or strategic announcement evident.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.